MolDX Open Public Meetings

Per CMS Internet Only Manual (IOM), Publication 100-08, Medicare Program Integrity Manual, Chapter 13.2.4.4, "After the proposed LCD is made public, MACs shall hold open meetings to discuss the review of the evidence and the rationale for the proposed LCD(s) with stakeholders in their jurisdiction."

An Open Meeting is scheduled by the Medical Director(s) after a proposed LCD is posted. The open meeting takes place during the 45-day comment period.

This meeting is for the oral presentation of comments and for stakeholders interested in listening to the comments. For oral comments to be included in the review and consideration of the proposed LCD, these comments must also be submitted in writing through the formal comment process during the comment period.

Registration

Registration is required for those that wish to present comments, and registration is encouraged for those that wish to listen to the meeting. To register for an Open Meeting, please use the link found in the "Upcoming Meetings" table below.

If you are submitting a presentation, all final presentations must be submitted to openmeeting@noridian.com by the due date listed below.

There are no meetings currently scheduled.

Previous Meeting Documents and Recordings

State Date Agenda Topics Recordings
All 10/08/25
  • MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
  • MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer
  • MolDX: Genetic Testing for Hereditary Thrombophilia
  • Agenda
Recording and Transcript
All 08/27/25
  • MolDX: Biomarker Testing for Risk Stratification in DCIS
  • Agenda
Recording and Transcript
All 08/26/25
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection
  • Agenda
Recording and Transcript
All 10/10/24
  • MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis
  • MolDX: Genetic Testing for Heritable Thoracic Aortic Disease
  • Agenda
Recording and Transcript
All 09/13/24
  • MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms
  • Agenda
Recording and Transcript
All 10/11/23
  • MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
  • MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
  • MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
  • Agenda
Recording and Transcript
All 09/20/23
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection
  • Agenda
Recording and Transcript
All 07/18/23
  • MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
  • Agenda
Recording and Transcript
All 10/20/22
  • MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
  • Agenda
Recording and Transcript
All 08/11/22
  • MolDx: Molecular Assays for the Diagnosis of Cutaneous Melanoma
  • MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer
  • Agenda
Recording and Transcript
All 05/26/22
  • Lumbar Epidural Injections
  • MolDX: 4 KScore® Assay
  • MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia
  • Nerve Blockade for Treatment of Chronic Pain and Neuropathy
  • Agenda
Recording and Transcript
All 2/24/22
  • LCD: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease
  • LCD: MolDX: Plasma-Based Genomic Profiling in Solid Tumors
  • LCD: Epidural Steroid Injections for Pain Management
  • Agenda
Recording and Transcript
All 06/24/21
  • MolDX: Melanoma Risk Stratification Molecular Testing
  • MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
  • MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
  • MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes
  • Agenda
Recording and Transcript
All 10/28/20
  • MolDX: Minimal Residual Disease Testing for Cancer
  • Agenda
Recording and Transcript
All 06/04/20
  • MolDX: Liquid Biopsies for Solid Organ Transplantation
  • MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer
  • Agenda
Recording and Transcript
All 06/03/20
  • MolDX: Breast Cancer Index (BCI) Gene Expression Test
  • MolDX: EndoPredict Breast Cancer Gene Expression Test
  • MolDX: Phenotypic Biomarker Detection in Circulating Tumor Cells
  • Agenda
Recording and Transcript
All 10/22/19
  • MolDX: Molecular Microscope® Diagnostic System for the Heart
  • MolDX: SelectMDx for Prostate Cancer
  • MolDX: Signatera and Minimal Residual Disease Testing for Colorectal Cancer
  • MolDX: Tests on allograft kidney biopsy tissue to assess for graft rejection
  • MolDX: Oncotype AR-V7 Nucleus Detect for Men with Metastatic Castrate Resistant Prostate Cancer (MCRPC)
  • MolDX: DecisionDX Melanoma
  • MolDX: Razor 14-Gene Lung Cancer Assay
  • MolDX: Repeat Germline Testing
  • MolDX: AlloSure® Cell-Free DNA Testing
  • MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with Favorable Intermediate Risk Disease
  • MolDX: Combinatorial Pharmacogenomics Limited Coverage
  • MolDX - Pharmacogenomics Testing
  • MolDX: Erythrocyte Molecular Antigen Typing
Recording and Transcript
All 05/30/19
  • MolDX: Next-Generation Sequencing for Solid Tumors
  • MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
  • MolDX: Pigmented Lesion Assay
Recording and Transcript
Last Updated Apr 14 , 2026